Suchen
Telix Pharmaceuticals Ltd
TLXZur Watchlist hinzufügen
11.950USD
+0.640+5.66%
Handelsschluss 09-22 16:00（ET）
0.00Marktkapitalisierung
0.00KGV TTM
Vorbörsliches Trading 05:27 (ET)11.570USD-0.380-3.18%
Vorbörsliches Trading 05:27 (ET)Über Telix Pharmaceuticals Ltd Unternehmen
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
Telix Pharmaceuticals Ltd Profil
BörsenkürzelTLX
Name des UnternehmensTelix Pharmaceuticals Ltd
IPO-datumNov 15, 2017
CEOOrtiz (Raphaeel)
Anzahl der mitarbeiter- -
WertpapierartDepository Receipt
Geschäftsjahresende- -
Addresse55 Flemington Road
StadtMELBOURNE
BörseNASDAQ OMX - NASDAQ BASIC
LandAustralia
Postleitzahl3051
Telefon61390933855
Websitehttps://telixpharma.com/
BörsenkürzelTLX
IPO-datumNov 15, 2017
CEOOrtiz (Raphaeel)
Führungskräfte von Telix Pharmaceuticals Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Christian P. (Chris) Behrenbruch, J.D., Ph.D.
Dr. Christian P. (Chris) Behrenbruch, J.D., Ph.D.
Group Chief Executive Officer, Managing Director, Executive Director
Group Chief Executive Officer, Managing Director, Executive Director
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Ms. Jann Skinner
Ms. Jann Skinner
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. David Cade, M.D.
Dr. David Cade, M.D.
Group Chief Medical Officer
Group Chief Medical Officer
--
--
Mr. Darren Smith, CPA
Mr. Darren Smith, CPA
Group Chief Financial Officer
Group Chief Financial Officer
--
--
Dr. Darren Patti, Pharm.D.
Dr. Darren Patti, Pharm.D.
Group Chief Operating Officer
Group Chief Operating Officer
--
--
Ms. Marie McDonald
Ms. Marie McDonald
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. David Gill
Mr. David Gill
Non-Executive Chair of the Board
Non-Executive Chair of the Board
--
--
Ms. Shomalin Naidoo
Ms. Shomalin Naidoo
Interim Company Secretary
Interim Company Secretary
--
--
Dr. Maria Rivas, M.D.
Dr. Maria Rivas, M.D.
Additional Non-Executive Director
Additional Non-Executive Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Christian P. (Chris) Behrenbruch, J.D., Ph.D.
Dr. Christian P. (Chris) Behrenbruch, J.D., Ph.D.
Group Chief Executive Officer, Managing Director, Executive Director
Group Chief Executive Officer, Managing Director, Executive Director
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Ms. Jann Skinner
Ms. Jann Skinner
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. David Cade, M.D.
Dr. David Cade, M.D.
Group Chief Medical Officer
Group Chief Medical Officer
--
--
Mr. Darren Smith, CPA
Mr. Darren Smith, CPA
Group Chief Financial Officer
Group Chief Financial Officer
--
--
Dr. Darren Patti, Pharm.D.
Dr. Darren Patti, Pharm.D.
Group Chief Operating Officer
Group Chief Operating Officer
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Telix Pharmaceuticals Ltd?
Die fünf größten Anteilseigner von Telix Pharmaceuticals Ltd sind: Dr. Christian P. (Chris) Behrenbruch, J.D., Ph.D.
Wie viele Institutionen halten Anteile an Telix Pharmaceuticals Ltd (TLX)?
Mit Stand vom 2026Q1 halten 61 Institutionen Anteile an Telix Pharmaceuticals Ltd, mit einem Gesamtmarktwert von etwa 1.47M, was 0.43% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 326197.00 gestiegen.